Shift in Cancer Research Translation
September 2014. Companies offering cancer diagnostics or drugs abound. A few successful products are efficient and evidence attractive opportunities for profit-making, which fuel investors’ fantasies in turn. However translation of cancer research into a broader spectrum of tangible clinical results – paediatric or geriatric ones ¬ continues to fall short of high hopes.
Christof von Kalle, at the time Head of the National Center for Tumor Diseases (NCT) at Heidelberg provides a sense of how wishful wangling or group think lead up to dead ends in personalised medicine. What is at issue in research on checkpoint inhibitors, cancer stem cells, myelodysplastic syndromes, lung cancers or other tumours? How beneficial are the European Medicines Agency’s or the UK pharma’s initiatives to open up access to clinical trials data for R&D centres like NCT? What about French regulatory requirements? When does a hype of research about molecular cancer biomarkers achieve the opposite? An enriching perspective on delicate issues.Reading time: 26 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Bayer AG: New stakes in stem cells
Andreas Busch, Head of Global Drug Discovery on results, technology platforms, and expectations
Metrics for Health and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle (US)